Real-World Outcomes In Resected Stage Ib-Iiia Egfr Mutated Nsclc In Canada: Analysis From The Potent Study

Among patient (pts) who have advanced NSCLC with EGFR driver mutations (EGFRm), most benefit from EGFR tyrosine kinase inhibitors (TKIs). The ADAURA trial showed significant improvement in disease-free survival (DFS) with the addition of the EGFR TKI, osimertinib, in resected early stage (IB-IIIA) EGFRm NSCLC pts. The objective of the POTENT study was to estimate EGFRm prevalence and assess outcomes in resected early stage EGFRm NSCLC in real-world setting in Canada.